



Division of Laboratory Systems

Public-Private Laboratory Partnerships for Public Health Emergency Response and Surveillance

Jasmine Chaitram, MPH

Associate Director for Laboratory Preparedness

Division of Laboratory Systems



About DLS

Vision

Exemplary laboratory practice and systems strengthen clinical care, public health, emergency response, and health equity.

Mission

Improve public health, patient outcomes, and health equity by advancing laboratory systems.

Clinical Laboratory Community Outreach



Laboratory Outreach Communication System (LOCS)

- CDC's top 10 most subscribed eNewsletter
- Over **104,000** recipients
- Subscribe: LOCS@cdc.gov




LOCS Calls (formerly Clinical Laboratory COVID-19 Response Calls)

- Over **3,700** organizations have participated
- **60%** of attendees work in healthcare or government

Zika 2016



Estimated Potential Range of *Aedes aegypti* in the United States, 2017



<https://www.cdc.gov/about/24-7/cdcresponders-zika/>

MOU for Surge Testing

- Objectives
 - Supplement PHL testing capacity
 - Improve coordination and communication
 - Ensure commercial laboratories have access to appropriate resources
 - Engage commercial laboratories early in the response to maximize resources
 - Common understanding of test performance requirements, following testing algorithms, and result reporting requirements
 - Exercises and continuous collaboration and communication

[2022 Revised MOU for Surge Capacity_Final_sb AMP signed ACLA signed CSTE.pdf \(cdc.gov\)](#)



Extensive Testing Needs During COVID-19





COVID-19 CDC and Commercial Laboratory Collaboration

- Early information sharing
- Tested millions of clinical specimens
- Performed sequencing under contract to provide insights on prevalence and transmission in the United States
 - Thousands of sequences/week
- Collected and tested specimens for seroprevalence studies




Beginning of the Mpox Outbreak in the U.S.

- First case was diagnosed in May 2022
 - Cases identified in every U.S. state, peaking to over 400 cases/week
- Diagnostic test available to several public health laboratories that are members of the Laboratory Response Network (LRN) at the beginning of the outbreak
 - Estimated capacity 8,000 tests/week




Collaboration for Mpox Outbreak Response

- Collaborated with the American Clinical Laboratory Association (ACLA) to identify 5 national, independent commercial laboratories to support mpox testing
- Extended authorization of a CDC developed, FDA-cleared non-variola orthopoxvirus assay
- Over the span of several weeks, CDC provided training, access to procedures and reagents, and materials for verification testing
- Commercial laboratories conducted studies to add other extraction methods and platforms to the CDC cleared assay
- Facilitated electronic and standardized reporting of test results to state health departments and CDC



MPX/NVO Testing Capacity Increased Significantly



**Total testing capacity, as described in press releases:

May 26 - 6840; June 21 - 8,000; June 28 - 10,000; July 6 - 20,000; July 11 - 30,000; July 13 - 60,000; July 14 - 70,000; July 18 - 80,000¹

1. <https://www.whitehouse.gov/briefing-room/statements-releases/2022/08/02/president-biden-announces-team-to-lead-monkeypox-response/>

Importance of Public-Private Partnerships



- Leverage relationships and systems between healthcare providers and commercial laboratories
- Provide high-volume testing and improved nationwide access to testing
- Improve testing turnaround time
- Improve public health surveillance through access to thousands of clinical specimens and sequencing capabilities
- Diversify public health tests through commercial development of assays and assistance with validation studies for high-throughput instruments and reduced biosafety risks
- Improve CDC testing guidance based on experience of the private sector
- Strengthen scientific collaborations for special studies and surveillance

Thank you!



Questions?





For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

Images used in accordance with fair use terms under the federal copyright law, not for distribution.

Use of trade names is for identification only and does not imply endorsement by U.S. Centers for Disease Control and Prevention.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of Centers for Disease Control and Prevention.